stockrow
Friday 6 November 2026
Export TLX’s income statement to Excel — free account
Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited’s revenue for fiscal 2025 (year ended December 2025) was $803.8 million, up 55.6% from fiscal 2024.
9.65
0.23
+2.44%
Follow TLX
Alert me
Telix Pharmaceuticals Limited (TLX) Free cash flow margin
Telix Pharmaceuticals Limited's free cash flow margin over the twelve months to 30 June 2026 was 0.00%, up 7.6 percentage points from fiscal 2025 (−7.60%). That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | −7.60% | (8.63) |
| FY2024 | 1.03% | (1.57) |
| FY2023 | 2.60% | — |
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| TARS Tarsus Pharmaceuticals, Inc. compare | 4.76% |
| ELVN Enliven Therapeutics, Inc. compare | 0.00% |
| DYN Dyne Therapeutics, Inc. compare | 0.00% |
| CELC Celcuity, Inc. compare | 0.00% |
| TLX Telix Pharmaceuticals Limited | 0.00% |
| VKTX Viking Therapeutics, Inc. compare | 0.00% |
| IDYA IDEAYA Biosciences, Inc. compare | −957.4% |
| VRDN Viridian Therapeutics, Inc. compare | −1,305.4% |
| DNLI Denali Therapeutics Inc. compare | −1,986.8% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue